JP2019529336A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529336A5
JP2019529336A5 JP2018566490A JP2018566490A JP2019529336A5 JP 2019529336 A5 JP2019529336 A5 JP 2019529336A5 JP 2018566490 A JP2018566490 A JP 2018566490A JP 2018566490 A JP2018566490 A JP 2018566490A JP 2019529336 A5 JP2019529336 A5 JP 2019529336A5
Authority
JP
Japan
Prior art keywords
seq
disease
amino acid
acid sequence
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018566490A
Other languages
English (en)
Japanese (ja)
Other versions
JP7029415B2 (ja
JP2019529336A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/067067 external-priority patent/WO2018011073A1/en
Publication of JP2019529336A publication Critical patent/JP2019529336A/ja
Priority to JP2021164366A priority Critical patent/JP7244600B2/ja
Publication of JP2019529336A5 publication Critical patent/JP2019529336A5/ja
Application granted granted Critical
Publication of JP7029415B2 publication Critical patent/JP7029415B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018566490A 2016-07-12 2017-07-07 過リン酸化タウに特異的な抗体およびその使用方法 Active JP7029415B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021164366A JP7244600B2 (ja) 2016-07-12 2021-10-05 過リン酸化タウに特異的な抗体およびその使用方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DKPA201600416 2016-07-12
DKPA201600416 2016-07-12
DKPA201700005 2017-01-04
DKPA201700008 2017-01-04
DKPA201700005 2017-01-04
DKPA201700008 2017-01-04
DKPA201700179 2017-03-14
DKPA201700179 2017-03-14
PCT/EP2017/067067 WO2018011073A1 (en) 2016-07-12 2017-07-07 Antibodies specific for hyperphosphorylated tau and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021164366A Division JP7244600B2 (ja) 2016-07-12 2021-10-05 過リン酸化タウに特異的な抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2019529336A JP2019529336A (ja) 2019-10-17
JP2019529336A5 true JP2019529336A5 (enExample) 2021-11-18
JP7029415B2 JP7029415B2 (ja) 2022-03-03

Family

ID=60941665

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018566490A Active JP7029415B2 (ja) 2016-07-12 2017-07-07 過リン酸化タウに特異的な抗体およびその使用方法
JP2021164366A Active JP7244600B2 (ja) 2016-07-12 2021-10-05 過リン酸化タウに特異的な抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021164366A Active JP7244600B2 (ja) 2016-07-12 2021-10-05 過リン酸化タウに特異的な抗体およびその使用方法

Country Status (41)

Country Link
US (6) US10472415B2 (enExample)
EP (2) EP3878864A1 (enExample)
JP (2) JP7029415B2 (enExample)
KR (1) KR102551971B1 (enExample)
CN (2) CN116041504A (enExample)
AU (2) AU2017295608B2 (enExample)
BR (1) BR112018004916A2 (enExample)
CA (1) CA3027561A1 (enExample)
CL (1) CL2019000082A1 (enExample)
CO (1) CO2018014325A2 (enExample)
CY (1) CY1123995T1 (enExample)
DK (1) DK3484916T3 (enExample)
DO (1) DOP2018000281A (enExample)
EC (1) ECSP19005417A (enExample)
ES (1) ES2862427T3 (enExample)
GE (1) GEP20217222B (enExample)
HR (1) HRP20210522T1 (enExample)
HU (1) HUE053679T2 (enExample)
IL (1) IL263530B2 (enExample)
JO (1) JOP20180117B1 (enExample)
LT (1) LT3484916T (enExample)
MA (2) MA56165A (enExample)
MX (1) MX2019000476A (enExample)
MY (1) MY197836A (enExample)
NI (1) NI201900003A (enExample)
NZ (1) NZ748983A (enExample)
PE (1) PE20190227A1 (enExample)
PH (1) PH12018502613B1 (enExample)
PL (1) PL3484916T3 (enExample)
PT (1) PT3484916T (enExample)
RS (1) RS61646B1 (enExample)
RU (1) RU2760875C1 (enExample)
SG (1) SG11201811015RA (enExample)
SI (1) SI3484916T1 (enExample)
SM (1) SMT202100194T1 (enExample)
SV (1) SV2019005807A (enExample)
TN (1) TN2018000419A1 (enExample)
TW (1) TWI747922B (enExample)
UA (1) UA124104C2 (enExample)
WO (1) WO2018011073A1 (enExample)
ZA (1) ZA201808329B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5422782B1 (ja) 2012-12-21 2014-02-19 独立行政法人放射線医学総合研究所 脳内に蓄積したタウタンパク質をイメージングするための新規化合物
NZ775762A (en) 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
JP7029415B2 (ja) 2016-07-12 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 過リン酸化タウに特異的な抗体およびその使用方法
EP3551655A2 (en) 2016-12-07 2019-10-16 Genentech, Inc. Anti-tau antibodies and methods of their use
EP3551220B1 (en) 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
US10995137B2 (en) 2017-01-04 2021-05-04 H. Lundbeck A/S Antibodies specific for hyperphosphorlated tau for the treatment of ocular diseases
CA3053379A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
WO2019149798A1 (en) * 2018-02-01 2019-08-08 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
TW201946654A (zh) * 2018-03-05 2019-12-16 比利時商健生藥品公司 抗PHF-Tau抗體及其用途
CN112384517B (zh) 2018-05-09 2023-07-14 新旭生技股份有限公司 杂芳基化合物及其用途
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2020123492A1 (en) * 2018-12-10 2020-06-18 New York University Monoclonal antibodies targeting c-terminal region of phosphorylated tau
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
CN113748343A (zh) 2019-03-28 2021-12-03 H.隆德贝克有限公司 pS396测定用于诊断TAU蛋白病的用途
TWI832183B (zh) 2019-08-06 2024-02-11 香港商新旭生技股份有限公司 結合至病理性tau種類之抗體及其用途
CA3161455A1 (en) 2019-11-13 2021-05-20 Aprinoia Therapeutics Limited Compounds for degrading tau protein aggregates and uses thereof
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
WO2023008415A1 (ja) 2021-07-27 2023-02-02 STAND Therapeutics株式会社 ペプチドタグおよび当該ペプチドタグをコードする核酸
JP2024530408A (ja) * 2021-08-06 2024-08-21 ハー・ルンドベック・アクチエゼルスカベット LC-MSによるヒト脳脊髄液中の高リン酸化Tauの決定方法
JP2024534053A (ja) * 2021-08-25 2024-09-18 アイバイオ, インク. 抗cd25抗体
AU2024367338A1 (en) * 2023-10-24 2026-04-30 Ac Immune Sa Method of treating preclinicial alzheimer's disease

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2065299C (en) 1989-08-09 2001-07-24 Buck A. Rhodes Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
WO1993011231A1 (en) 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム インターナショナル,インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
AU693436B2 (en) 1993-03-09 1998-07-02 Genzyme Corporation Isolation of components of interest from milk
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
CN1399645A (zh) 1999-07-29 2003-02-26 米德列斯公司 Her2/neu的人单克隆抗体
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US20030162230A1 (en) 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
AT500379B8 (de) * 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
WO2007019273A2 (en) 2005-08-04 2007-02-15 Albert Einstein College Of Medicine Of Yeshiva University Phosphorylation of tau by abl
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル.エル.シー. Hco32およびhco27、ならびに関連実施例
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
EP4218794A3 (en) 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
WO2012045882A2 (en) * 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
LT2627672T (lt) * 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
WO2012162179A1 (en) * 2011-05-20 2012-11-29 Oligomerix, Inc. Tau protease compositions and methods of use
JP6358953B2 (ja) * 2011-10-07 2018-07-18 エーシー イミューン エス.エー. タウを認識するホスホ特異的抗体
CA2869438C (en) 2012-04-05 2021-08-17 Ac Immune S.A. Humanized tau antibody
EP2870176A4 (en) 2012-07-03 2016-09-28 Univ Washington ANTIBODIES DIRECTED AGAINST TAU
EP2885010B1 (en) 2012-08-16 2020-01-01 Ipierian, Inc. Methods of treating a tauopathy
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
WO2014170549A1 (en) 2013-04-16 2014-10-23 Glykos Finland Oy A method for generating induced pluripotent stem cells
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
MX383789B (es) 2014-01-23 2025-03-14 Asahi Chemical Ind Composicion de copolimero de bloque y composicion adhesiva.
EP3166688B1 (en) 2014-07-08 2024-08-21 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
JO3711B1 (ar) * 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
JP7029415B2 (ja) 2016-07-12 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 過リン酸化タウに特異的な抗体およびその使用方法
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
US10995137B2 (en) 2017-01-04 2021-05-04 H. Lundbeck A/S Antibodies specific for hyperphosphorlated tau for the treatment of ocular diseases
US10934438B2 (en) 2017-04-27 2021-03-02 Axalta Coating Systems Ip Co., Llc Coatings and methods for using and producing the same

Similar Documents

Publication Publication Date Title
JP7244600B2 (ja) 過リン酸化タウに特異的な抗体およびその使用方法
Bussière et al. Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Aβ immunotherapy on their clearance
JP6518727B2 (ja) 病理学的タウタンパク質の免疫学的標的化方法
Sigurdsson Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies
Schroeder et al. Tau-directed immunotherapy: a promising strategy for treating Alzheimer’s disease and other tauopathies
RU2645259C2 (ru) Терапия и диагностика на основе белков тау-опосредуемой патологии при болезни альцгеймера
Shahaduzzaman et al. Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson’s disease
Landlinger et al. Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer’s disease
RU2657438C2 (ru) Терапевтическое средство или профилактическое средство против деменции
Cynis et al. Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges
JP2012522754A5 (enExample)
SA520411188B1 (ar) جسم مضاد مربوط بالفا - ساينوكلين نشط
JP2016501247A (ja) 抗Aβ抗体を使用して脳アミロイド斑を減少させる方法
Doucet et al. Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles
KR20110011596A (ko) 아밀로이드증의 치료 및 예방
Teaktong et al. Nicotinic acetylcholine receptor immunohistochemistry in Alzheimer's disease and dementia with Lewy bodies: differential neuronal and astroglial pathology
JP2015517502A (ja) 卒中後の神経形成を促進するためのセマフォリン−4d結合分子の使用
JP6611858B2 (ja) D3から誘導されたd−エナンチオマーの新規ペプチド及びその使用
CN104379167B (zh) 用于中风和缺血或缺血性病况的人抗体及其特异性结合序列
Levites et al. A human monoclonal IgG that binds Aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo
Levigoureux et al. Binding of the PET radiotracer [18F] BF227 does not reflect the presence of alpha-synuclein aggregates in transgenic mice
Wang et al. Intramuscular delivery of a single chain antibody gene prevents brain Aβ deposition and cognitive impairment in a mouse model of Alzheimer’s disease
Li et al. Novel naturally occurring autoantibodies attenuate α‐synuclein pathology in a mouse model of Parkinson's disease
Triplett et al. Active immunization targeting amyloid β for the treatment of Alzheimer’s disease
CN101506231A (zh) 筛选具有抗淀粉样蛋白性质的化合物的方法